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Abstract
Background—Chronic lung diseases are increasingly recognized complications of vertically-
acquired HIV among adolescents in sub-Saharan Africa and may manifest with hypoxia or 
tachypnea. We sought to determine the prevalence of and risk factors for hypoxia and tachypnea 
among adolescents with vertically-acquired HIV in Nairobi, Kenya.
Methods—We performed a cross-sectional analysis of 258 adolescents with vertically-acquired 
HIV who were initiating care at the Coptic Hope Center for Infectious Diseases. Adolescents with 
documented pneumonia were excluded. Hypoxia was defined as resting oxygen saturation ≤92%, 
and tachypnea was based on the 99th percentile of age-appropriate respiratory rates. Logistic 
regression models adjusted for demographics and HIV severity estimated odds ratios (ORs) for 
risk of hypoxia and tachypnea associated with potential risk factors.
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Results—Overall, 11% of adolescents had hypoxia and 55% had tachypnea. Advanced HIV 
(adjusted OR [aOR] 2.41) and low CD4 (aOR 1.74) were associated with greater hypoxia risk, but 
confidence intervals (CI) were wide and included the null (95% CI 0.93–6.23 and 0.69–4.39, 
respectively). Low CD4 (aOR 2.45, 95% CI 1.39–4.32), current ART use (aOR 0.48, 95% CI 
0.27–0.86) and stunted growth (aOR 3.46, 95% CI 1.94–6.18) were associated with altered 
tachypnea risk.
Conclusions—Hypoxia and tachypnea are common among adolescents with vertically-acquired 
HIV. There was a suggestion that advanced HIV and low CD4 were associated with greater 
hypoxia risk. Low CD4, lack of ART use and stunted growth are risk factors for tachypnea. Our 
findings highlight the chronic lung disease burden in this population and may inform diagnostic 
algorithms.
Keywords
Vertically-acquired HIV; adolescents; chronic lung disease; hypoxia; tachypnea
INTRODUCTION
Over 3 million HIV-infected children and adolescents live in sub-Saharan Africa, and nearly 
all of them acquired HIV through vertical transmission.1 Lung diseases, such as lymphocytic 
interstitial pneumonia, recurrent pneumonia, tuberculosis and bronchiectasis, are well-
described among HIV-infected children <10 years old in sub-Saharan Africa2 and may also 
affect adolescents. The spectrum of pulmonary complications among HIV-infected 
adolescents in these settings additionally includes the chronic lung diseases: obliterative 
bronchiolitis, pulmonary hypertension and asthma.3 However, limited availability of chest 
radiography and lung function testing hinders definitive diagnosis.4
Respiratory abnormalities, such as hypoxia and tachypnea, are often manifestations of lung 
disease,5–7 and their presence may aid in identifying HIV-infected adolescents with chronic 
lung diseases. Among adolescents with vertically-acquired HIV in Zimbabwe who had no 
acute respiratory symptoms, 13% had hypoxia at rest and 28% were tachypneic.3 Over 40% 
had lung function abnormalities or radiographic evidence of chronic lung disease. However, 
risk factors for chronic lung diseases and their manifestations are not well-defined among 
adolescents with vertically-acquired HIV in resource-limited settings. As oxygen saturation 
and respiratory rate are frequently measured during routine clinic visits, we conducted this 
study to determine: a) the prevalence of hypoxia and tachypnea among adolescents with 
vertically-acquired HIV in Nairobi, Kenya; and b) risk factors for hypoxia and tachypnea 
among these adolescents.
METHODS
Study design and population
We performed a cross-sectional analysis of data from adolescents with vertically-acquired 
HIV who were initiating care at the Coptic Hope Center for Infectious Diseases in Nairobi 
from 2004 to 2013. The Hope Center provides comprehensive care to HIV-infected 
individuals according to Kenyan guidelines.8 Data were abstracted from electronic research 
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records populated with information from initial clinic visits. University of Washington and 
Kenyatta National Hospital Institutional Review Boards approved this study.
We restricted eligibility age to 10–16.9 years old because data supporting vertical HIV 
transmission, including documentation of HIV risk factors and maternal/sibling HIV status, 
were systematically collected for this age group. To identify baseline respiratory 
abnormalities, we excluded adolescents with documented pneumonia at initial clinic visits. 
Of 258 eligible adolescents, 56 did not have recorded oxygen saturation. We retained these 
adolescents in our overall cohort as characteristics of adolescents with and without 
documented oxygen saturation were similar.
Respiratory abnormalities
We defined hypoxia as resting oxygen saturation ≤92% by pulse oximetry.9 As normal 
respiratory rates vary by age during adolescence, we defined tachypnea as a respiratory rate 
greater than the 99th percentile of age-appropriate values (Table 1).10 Few published 
guidelines define hypoxia and tachypnea at Nairobi’s altitude of ~1,700 meters;9 therefore, 
to minimize the likelihood that our outcome definitions misclassified adolescents with 
normal oxygen saturation and respiratory rate into abnormal groups, we also considered 
more conservative cutoffs for oxygen saturation (≤90%) and respiratory rate (Table 1).
Potential risk factors
Baseline demographics included age and gender. Stunted growth and malnutrition were 
defined as height-for-age and body mass index (BMI)-for-age Z-scores < −2, respectively.11 
HIV severity was categorized per World Health Organization (WHO) clinical staging 
criteria. Advanced HIV was defined as WHO HIV stages 3 and 4. Current antiretroviral 
therapy (ART) and co-trimoxazole use were based on self-report. CD4 count (cells/μL) was 
measured within 30 days of care initiation. We defined low CD4 as <200 cells/μL. Indoor 
biofuel burning was based on self-reported use of wood, charcoal or kerosene as energy 
sources within the adolescent’s home.
Statistical analysis
To determine independent associations of each of the covariates in Tables 2 and 3 with 
hypoxia and tachypnea, we generated multivariable logistic regression models. Final models 
included age (continuous) and gender to account for potential confounding. We also adjusted 
for WHO HIV stage to minimize potential selection bias, as HIV-infected adolescents who 
are ill may be more likely to seek medical care.12 We repeated these analyses using 
conservative cutoffs for hypoxia and tachypnea.
All analyses were performed using Stata 13 (Stata Corp., College Station, TX).
RESULTS
Cohort characteristics
Most adolescents were at the lower end of included ages (51% were 10–12.9 years old); 
49% were male, 40% had stunted growth and 19% were malnourished. Overall, 34% had 
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WHO HIV stage 3/4, 28% reported current ART use and 51% reported taking co-
trimoxazole. Median CD4 was 326 cells/μL (interquartile range 125–549), and 33% had 
CD4 <200 cells/μL. A substantial proportion of data was missing for indoor biofuel burning 
exposure; among adolescents for whom data were available, 53% reported exposure.
Overall, 22 of 202 adolescents (11%) had hypoxia (oxygen saturation ≤92%), and 143 of 
258 (55%) had tachypnea (Table 1). When applying conservative outcome definitions, 13 
(6%) had hypoxia and 60 (23%) had tachypnea.
Risk factors for hypoxia
On average, adolescents with hypoxia were younger than those without hypoxia (per one 
year, adjusted odds ratio [aOR] 0.81, 95% confidence interval [CI] 0.66–0.99; Table 2). 
Advanced HIV was associated with greater risk for hypoxia: 55% of adolescents with 
hypoxia but only 31% of those without hypoxia had advanced HIV (aOR 2.41, 95% CI 
0.93–6.23). Ten of the 22 adolescents with hypoxia (45%) had low CD4, in contrast to 31% 
of those without hypoxia. This association persisted after adjustment for age, gender and 
WHO HIV stage (aOR 1.74), but, as with advanced HIV, the small number of subjects led to 
a statistically imprecise result (95% CI 0.69–4.39). Adolescents with hypoxia were more 
likely to report indoor biofuel burning; however, the extent of missing data prohibited any 
meaningful conclusions to be drawn.
In sensitivity analyses, using oxygen saturation ≤90% as the outcome, the association with 
advanced HIV was further attenuated (aOR 1.49, 95% CI 0.65–4.45), while the association 
with low CD4 was not substantially changed (aOR 1.96, 95% CI 0.63–6.05). The association 
with younger age remained similar (aOR 0.68, 95% CI 0.53–0.87).
Risk factors for tachypnea
Adolescents with tachypnea were younger on average than those without tachypnea (per one 
year, aOR 0.80, 95% CI 0.70–0.91; Table 3). Of adolescents with tachypnea, 51% had 
stunted growth compared to 26% of those without tachypnea (aOR 3.46, 95% CI 1.94–6.18). 
The prevalence of advanced HIV was 34% among those with and without tachypnea. Only 
22% with tachypnea were using ART compared to 36% of those without tachypnea (aOR 
0.48, 95% CI 0.27–0.86), and a greater proportion of adolescents with tachypnea had low 
CD4 (40% vs 25%; aOR 2.45, 95% CI 1.39–4.32). Exposure to indoor biofuel burning was 
more prevalent among those with tachypnea. Additionally adjusting these models for stunted 
growth did not appreciably alter associations (data not shown).
When using conservative cut-offs for tachypnea, associations with low CD4 (aOR 2.41, 95% 
CI 1.31–4.44), current ART use (aOR 0.26, 95% CI 0.11–0.62) and stunted growth (aOR 
3.78, 95% CI 1.98–7.22) were largely unchanged, but the association with age was 
diminished (aOR 0.95, 95% CI 0.82–1.10).
DISCUSSION
Hypoxia and tachypnea were common in this cohort of adolescents with vertically-acquired 
HIV in Nairobi. There was a suggestion that advanced HIV and low CD4 were associated 
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with greater risk of hypoxia. Low CD4, lack of ART and stunted growth were risk factors 
for tachypnea. These respiratory abnormalities may have clinically relevant implications. In 
a study of HIV-infected adolescents in Malawi, chronic lung disease phenotypes were 
characterized as hypoxia- or cough-predominant.7 Although pathologic correlates were not 
available in that study or in ours, specific combinations of routinely ascertained signs and 
symptoms may contribute to future clinical algorithms for identifying adolescents with 
chronic lung diseases in resource-limited settings. Most risk factors identified in our study 
are modifiable and may be amenable targets for mitigating the burden of chronic lung 
diseases.
HIV-related immunosuppression was associated with hypoxia and tachypnea. While WHO 
HIV stages 3/4 encompass prior severe and AIDS-defining illnesses, low current CD4 
imparts contemporaneous risk of opportunistic infections and non-infectious 
comorbidities.13 Current CD4 may reflect immunosuppression that has persisted for weeks, 
months or years. Longstanding HIV infection in children during critical periods of immune 
system and organ development may influence organ injury and increase risk of chronic lung 
diseases of the parenchyma, airways and vasculature,2,3,7,14 potentially impairing gas 
exchange.5 Concurrently, pulmonary infections may trigger local inflammation and resultant 
destructive lung lesions. Though it is unclear from this cross-sectional study if severe 
immunosuppression indeed predisposes to hypoxia and tachypnea, and whether it is because 
of immune dysfunction or prior pulmonary infections, our findings suggest that hypoxia and 
tachypnea in adolescents with advanced HIV or low CD4 are common and may warrant 
further pulmonary evaluation where available.
We also detected an association of current ART use with lower tachypnea risk. ART scale-up 
has led to dramatic declines in morbidity and mortality, but <40% of eligible HIV-infected 
children and adolescents access ART in sub-Saharan Africa.1 Further, ART initiation at 
advanced HIV or lower CD4 may attenuate this observed risk reduction, as immune function 
defects and pulmonary parenchymal damage may not be completely reversible.3,14 The 
association of ART with tachypnea suggests that immune modulation and pulmonary 
infection mitigation by ART has important implications for pulmonary pathophysiology, 
underscoring potential benefits of early, universal ART.
We also found that stunted growth was a strong predictor of tachypnea. In our cohort, 40% 
of adolescents had stunted growth, which is reported in as many as 50% of HIV-infected 
children and is linked with advanced HIV.15 Adolescents with stunted growth who acquired 
HIV vertically may have impaired lung development, as lung development is physiologically 
associated with growth velocity and height attainment. If adequate growth attainment does 
not occur by five years of age, impaired lung function may persist into adulthood,16 raising 
the concern that sequelae of stunted growth identified during adolescence may be 
irreversible. Stunted growth reflects long-term exposures and may capture elements of 
socioeconomic status, such as wealth, education and environmental conditions.17
Finally, we found that younger age was associated with greater hypoxia and tachypnea risk, 
potentially suggesting a survivor bias. In sub-Saharan Africa, adolescents with delayed 
diagnosis of vertically-acquired HIV often present at advanced HIV stages12 with stunted 
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growth, frequent infections and respiratory abnormalities.18 These “slow progressors” 
comprise up to 36% of infants with vertically-acquired HIV and may survive a median 16 
years without ART.19 As adolescents with untreated HIV have a high mortality risk,12 many 
with undiagnosed, advanced HIV will have died, some with respiratory abnormalities, prior 
to seeking care. However, we pose this hypothesis cautiously as the association with age was 
attenuated when data were analyzed using conservative cutoffs for tachypnea (though the 
association remained for hypoxia).
No consensus guidelines designate cutoffs for abnormal oxygen saturation or respiratory rate 
at Nairobi’s moderate altitude. However, altitude-specific models estimate a hypoxia 
threshold of 95% oxygen saturation,9 indicating that this altitude is unlikely to impact 
hypoxia prevalence. We observed tachypnea among 55% of adolescents compared to 28% in 
the Zimbabwean study. Applying that study’s cut-off (>25 breaths per minute) in our cohort 
yields a 42% tachypnea prevalence. Though unlikely, it remains possible that Nairobi’s 
altitude accounts for a fraction of our observed tachypnea prevalence.
Our study has several other limitations. First, the sample size was relatively small, 
representing only adolescents initiating care at the Hope Center who met criteria for 
vertically-acquired HIV. Second, vertically-acquired HIV criteria were based on self-report, 
which may have resulted in some misclassification. However, the median age for sexual 
debut in Kenya is 17–24 years old,20 supporting that the majority of adolescents in our 
cohort acquired HIV vertically. Third, the substantial proportion of missing data for indoor 
biofuel burning limited our ability to draw conclusions about associations regarding this 
exposure. Finally, despite controlling for potential confounding factors, there may still be 
residual confounding of associations.
In conclusion, hypoxia and tachypnea were common among adolescents with vertically-
acquired HIV. The association of advanced HIV, low CD4 and lack of ART with greater risk 
of hypoxia or tachypnea suggests that sequelae of uncontrolled HIV may contribute to 
pulmonary injury. Stunted growth, especially in HIV, may impact lung development. As the 
prevalence of adolescents with vertically-acquired HIV in sub-Saharan Africa is not 
anticipated to decline for another decade,19 further studies are needed to understand 
implications of these respiratory abnormalities and to determine whether they can be utilized 
systematically to identify chronic lung diseases among HIV-infected adolescents in 
resource-limited settings.
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